Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

3(75.0%)

Phase 3

1(25.0%)

4Total

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05680818Phase 3Active Not Recruiting

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Role: lead

NCT05227287Active Not Recruiting

ADH1 and ADH2 Disease Monitoring Study (DMS)

Role: lead

NCT07080385Phase 2Recruiting

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Role: lead

NCT05735015Phase 2Completed

PTH-independent Effects of Encaleret

Role: collaborator

NCT04581629Phase 2Completed

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Role: lead

All 5 trials loaded